Meridian Wealth Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-9,033
Closed -$596K 176
2024
Q3
$596K Sell
9,033
-22,584
-71% -$1.64M 0.1% 101
2024
Q2
$2.92M Buy
31,617
+846
+3% +$74.9K 0.52% 47
2024
Q1
$2.94M Buy
30,771
+3,082
+11% +$259K 0.55% 44
2023
Q4
$2.11M Sell
27,689
-90
-0.3% -$6.26K 0.46% 54
2023
Q3
$1.92M Sell
27,779
-800
-3% -$64.3K 0.48% 53
2023
Q2
$2.7M Buy
28,579
+1,233
+5% +$107K 0.65% 44
2023
Q1
$2.26M Buy
27,346
+4,253
+18% +$334K 0.57% 47
2022
Q4
$1.72M Buy
23,093
+436
+2% +$33.6K 0.44% 56
2022
Q3
$1.87M Sell
22,657
-3,410
-13% -$328K 0.53% 44
2022
Q2
$2.48M Buy
26,067
+944
+4% +$97.7K 0.66% 39
2022
Q1
$2.96M Buy
25,123
+2,254
+10% +$253K 0.69% 37
2021
Q4
$2.96M Buy
22,869
+2,524
+12% +$294K 0.72% 33
2021
Q3
$2.3M Buy
20,345
+1,081
+6% +$123K 0.64% 35
2021
Q2
$2M Buy
19,264
+5,548
+40% +$523K 0.56% 43
2021
Q1
$1.15M Buy
13,716
+4,977
+57% +$421K 0.38% 63
2020
Q4
$797K Buy
+8,739
New +$725K 0.29% 76

Other funds holding EW

Meridian Wealth Advisors's EW Position: Q4 2024 in Review

Meridian Wealth Advisors sold out of Edwards Lifesciences (EW) in Q4 2024, closing a stake of 9,033 shares — an estimated $596K sold.

Meridian Wealth Advisors first reported a position in EW in Q4 2020 and held it in 16 quarters. The position peaked at $2.96M in Q4 2021. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2024.

  • Meridian Wealth Advisors reported no remaining Edwards Lifesciences position as of Q4 2024 after selling out during the quarter.
  • Meridian Wealth Advisors sold 9,033 Edwards Lifesciences shares in Q4 2024, an estimated $596K.
  • Meridian Wealth Advisors first reported a position in Edwards Lifesciences in Q4 2020 and held it in 16 quarters.
  • Meridian Wealth Advisors's Edwards Lifesciences position peaked at $2.96M in Q4 2021.
  • 1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2024.

Based on Meridian Wealth Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.